

Single Preferred Drug List

As of January 1, 2019, the below medications will become **non-preferred (non-formulary)** for CHPW Managed Medicaid members, to align with the HCA Single Preferred Drug List.

ADRENAL HORMONES	
CORTEF TABLET	VERIPRED 20 ORAL SOLN
MEDROL TABLET	KENALOG-40 VIAL
ANTIMALARIALS	
DARAPRIM TABLET	
ANTIVIRALS	
ZIRGAN GEL	RELENZA INHALATION
VEMLIDY TABLETS	BARACLUDE ORAL SOLUTION
ACYCLOVIR OINTMENT	DENAVIR CREAM
BENIGN PROSTATIC HYPERTROPHY (BPH) THERAPY	
RAPAFLO CAPSULE	
BILE ACIDS	
CHOLBAM CAPSULE	
COMINATION ANTICHOLINERGICS	
BELLADONNA-PHENOBARBITAL TABLET	
GOUT THERAPY	
COLCRYS TABLET	ULORIC TABLET
ZURAMPIC TABLET	
HYPNOTIC AGENTS	
RESTORIL CAPSULE	FLURAZEPAM HCL CAPSULE
ESTAZOLAM TABLET	ZALEPLON CAPSULE
ESZOPICLONE TABLET	BELSOMRA TABLET
ANTIDEPRESSANTS	
MARPLAN TABLET	NARDIL TABLET
NEFAZODONE HCL TABLET	AMITRIPTYLINE/CHLORDIAZEPOXIDE TABLET
MAPROTILINE HCL TABLET	CITALOPRAM ORAL SOLN
FLUOXETINE DR CAPSULE	ESCITALOPRAM ORAL SOLN
SERTRALINE ORAL CONC	FLUVOXAMINE ER CAPSULE
PAROXETINE ER TABLET	VIIBRYD TABLET/DOSE PACK
IMIPRAMINE CAPSULE	NORTRIPTYLINE ORAL SOLN
PROTRIPTYLINE TABLET	TRIMIPRAMINE CAPSULE
CLOMIPRAMINE CAPSULE	
MISCELLANEOUS GASTROINTESTINAL AGENTS	
ENTOCORT EC DR CAPSULE	ANAPRAM-HC CREAM
PROCTOFOAM-HC FOAM	UCERIS AEROSOL

PSYCHOTHERAPEUTIC	
GUANIDINE HCL TABLET	
MISCELLANEOUS RHEUMATOLOGICAL AGENTS	
SAVELLA TABLET/DOSE PACK	
MUSCLE RELAXANTS & ANTISPASMODIC AGENTS	
TIZANIDINE CAPSULE	ORPHENADRINE ER TABLET
CHLORZOXAZONE TABLET	CARISOPRODOL TABLET
METAXALONE TABLET	DANTROLENE SOD CAPSULE
MYASTHENIA GRAVIS	
MESTINON	
STEROID-ANTIBIOTIC COMBINATIONS	
NEOMYCIN/POLYMYXIN/HC SUSP DROPS	NEOMYCIN/BACITRACIN/POLY/HC OINTMENT
NEO-POLYCIN HC OINTMENT	BLEPHAMIDE SUSP DROP
BLEPHAMIDE SOP OINTMENT	
XANTHINES	
ELIXOPHYLLIN ELIXIR	THOE-24 ER CAPSULE
MISCELLANEOUS AGENTS	
CERDELGA CAPSULE	

The following medications will change from formulary without a PA to **formulary with a PA**.

AMMONIA INHIBITORS	
LITHOSTAT TABLET	
BIPOLAR DISORDER	
EQUETRO ER TABLET	
TOPICAL AGENTS	
REGRANEX GEL	
SUBSTRATE REDUCING	
MIGLUSTAT CAPSULE	
GLUCOCORTICOIDS	
SOLU-CORTEF VIAL	DEXAMETHASONE SOLUTION
DEXAMETHASONE DROPS	
KIDNEY STONE AGENTS	
THIOLA TABLET	
RECTAL PREPARATIONS	
RECTIV OINTMENT	
MUCOLYTICS	
PULMOZYME INHALATION	
URINARY TRACT ANALGESICS	
ELMIRON CAPSULE	



2019 Medicare Part D Opioid Edits

Starting on **January 1, 2019**, in response to Centers for Medicare & Medicaid Services (CMS) guidance, there will be new limitations on opioid dispensing by pharmacies to Medicare Part D members.

Members who are residents of a long-term care facility, in hospice care, are receiving palliative or end-of-life care, or are being treated for active cancer-related pain are excluded from these limitations.

Buprenorphine products for medically assisted treatment (MAT) are excluded from the opioid edits.

Opioid edits at the pharmacy (point of sale):

- **NEW:** Initial opioid fills for acute pain treatment will be limited to no more than a 7-Day supply.
- **NEW:** Members using opioids at greater than 90 morphine equivalent dose (MME) per day will require the pharmacist to consult with the prescriber for care coordination.
- Safety alerts to pharmacist for abrupt dose escalation and/or initiation of therapy with a long-acting opioid.
- Drug interaction alerts to pharmacist identifying the concurrent prescribing of buprenorphine and opioids, or opioids and benzodiazepines.
- Warning to pharmacist of duplication of opioid therapy, and poly prescribing, or poly pharmacy history.

NEW: In addition to pharmacy level edits, CHPW pharmacy will be monitoring the safety and trends around opioid prescribing for our Medicare Part D members. As part of the new CMS guidance for 2019, we will have the ability to perform comprehensive medication reviews that may result in the restricting of members to one pharmacy and one prescriber for controlled substances for coordination of care and case management.

Pharmacists in Expanding MAT Access

You are invited to an upcoming webinar:

Pharmacist Roles in Expanding Access to Medication Assisted Treatment for Opioid Use Disorder

Join Albert Carbo, PharmD, and Regina Bonnevie Rogers, MD, Peninsula Community Health Services, and Andrea Corona, PharmD, BCACP, Providence Medical Group in Southwest Washington to:

- Learn about the scope of practice for pharmacists in Washington State, including delegated prescribing in medication assisted treatment (MAT) for opioid use disorder.
- Learn about how Peninsula Community Health Services has operationalized the pharmacist role in team-based strategies to provide MAT for patients with opioid use disorder.

Webinar: Pharmacist Roles in Expanding Access to Medication Assisted Treatment for Opioid Use Disorder

Date: Tuesday, November 27, 2018

Time: 8 AM – 9 AM Pacific

Registration Required: <https://uw-phi.zoom.us/meeting/register/ef5144727e59ee25cde7dc3c8da9331e>

This free presentation is sponsored by University of Washington AIMS Center and Alcohol and Drug Abuse Institute in collaboration with the Washington State Pharmacy Association.

Making Connections

We welcome your feedback and future topic ideas. Email us at: PharmacyR@chpw.org